COVID-19 is opening a door to a new era in drug development


With coronavirus disease 2019 (COVID-19) shutting down countries and economies, the world is expectantly looking at scientist to come up with a solution. Although the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coronavirus is fast and deadly, there is a serious arsenal of antivirals the scientific community is charging at SARS-CoV-2. The weaponry includes novel RNA vaccines, broad-spectrum virus inhibitors and even a cell therapy. Want to stay up-to-date with the latest on COVID-19? Receive the latest news direct to your inbox by becoming a member. Become a member  Tanel Mahlakõiv, PhD – Celularity Inc (NJ, USA) Tanel Mahlakõiv...

To view this content, please register now for access

It's completely free